IL-1β levels were comparable to those observed in canakinumab-treated patients with monogenic auto-inflammatory diseases driven by IL-1β, such as CAPS, FMF, MKD and TRAPS. Here, IL1B is linked to cryopyrin-associated periodic syndrome.